Results: 6

Neurotoxidad inducida por ifosfamida

Med. infant; 30 (3), 2023
Introducción: La ifosfamida es un agente alquilante utilizado para el tratamiento de enfermedades oncohematológicas. Entre sus eventos adversos agudos se encuentra la neurotoxicidad. Esta puede presentarse desde el inicio de la infusión hasta tres días después. El tratamiento consiste en suspender l...

Neutropenia febril postquimioterapia, Instituto de Oncología y Radiobiología
Febrile neutropenia after cytostatic therapy observed in the Institute of Oncology and Radiobiology

Rev. cuba. farm; 50 (1), 2016
Objetivo: caracterizar a los pacientes oncológicos que presenten episodios de neutropenia febril postquimioterapia ingresados en el Instituto de Oncología y Radiobiología en el periodo de enero a mayo del 2015. Métodos: se realizó un estudio descriptivo de corte transversal a una muestra de 36 pacie...

High-dose tamoxifen plus ifosfamide and anthracycline in a patient with angiosarcoma of the breast

West Indian med. j; 62 (7), 2013
Although breast cancer is, unfortunately, not uncommon in women, a mere 0.04% of malignant breast tumours are primary angiosarcomas. Chemotherapy is advocated for treatment of breast angiosarcomas; however, no guidelines exist regarding optimal chemotherapeutics or protocols. Presently, the prognosis for...

Gemcitabina e ifosfamida no tratamento do linfoma de Hodgkin refratário ou recidivado após múltiplas terapias: [carta ao editor]
Gemcitabine and ifosfamide in the treatment of Hodgkin's lymphoma refractory to or relapsed after multiple therapies: [letter to the editor]

Patients with Hodgkin's lymphoma relapsed after or refractory to multiple therapies (rHL) have a dismal prognosis. Monotherapy with gemcitabine can promote an overall response rate of about 40 percent in these patients and its association with alkylating agents can provide better results. We retrospectiv...

Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0

Rev. invest. clín; 54 (1), 2002
PURPOSE: To compare the hematopoietic recovery and the clinical outcome after high dose chemotherapy and peripheral blood stem cell (PBSC) transplant between patients who received recombinant granulocyte colony-stimulating factor (G-CSF) starting on day 0 and those who received it starting on day +7. PAT...

Rabdomiossarcoma subconjuntival: relato de um caso
Subconjuntival Rhabdomyosarcoma: case report

Arq. bras. oftalmol; 60 (2), 1997
É descrito um caso de rabdomiossarcoma epipulpar de localização subconjuntival em um paciente de 18 anos de idade. Foram realizados exames de tomografia computadorizada e biópsia da lesão para confirmação diagnóstica. O tratamento instituído consistiu em quimioterapia e radioterapia adicional pa...